HEPHAISTOS-Pharma

Immunotherapie revolutionnized the way cancer is treated, showing that patients could be treated. Unfortunately, only 1 out of 10 patients is cured, without relapse.

HEPHAISTOS is developping ONCO-boost, a drug that stimulates the immune system of patients, and increases the effiacy of antibodies used in immunotherapies to increase the cure rate above 60 - 80%. 

The main difference of ONCO-Boost with the competitors is its safety profile. Other immunostimulants are too toxic to be injected intravenously, and thus are limited to intratumoral injections, that reduces their effiacy and can't treat metastases. Our drug is the only one of its class to be injected intravenously thanks to its safety profile and unmatched solubility. 

We will start the clinical trials, with the first patient recruitment in 2 years. We are preparing the commercialization of our technology through partnerships and licence agreements with the leaders in the field of immuno-oncology.